NCT04541082 2025-12-18Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsJazz PharmaceuticalsPhase 1 Recruiting102 enrolled
NCT07061626 2025-07-11Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade GliomaPlus TherapeuticsPhase 1 Not yet recruiting56 enrolled
NCT03043391 2024-04-08Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in ChildrenIstari Oncology, Inc.Phase 1 Completed8 enrolled 9 charts
NCT02859857 2021-07-22Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid TumorsBexion Pharmaceuticals, Inc.Phase 1 Completed86 enrolled
NCT02502708 2020-06-04Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain TumorsLumos PharmaPhase 1 Completed81 enrolled
NCT00006368 2013-05-01Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerNovartisPhase 1 Completed60 enrolled